Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

ConclusionTreatment with selexipag did not reduce the number of RP attacks compared with placebo. The safety profile of selexipag was similar to that previously reported. This study provides important information about the feasibility of eDiary reporting of RP attacks in clinical trials.

Source: Arthritis and Rheumatism - November 28, 2017 Category: Rheumatology Authors: Christopher P. Denton, Éric Hachulla, Gabriela Riemekasten, Andreas Schwarting, Jean‐Marie Frenoux, Aline Frey, Franck‐Olivier Le Brun, Ariane L. Herrick, Tags: Original Article Source Type: research